{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:46:09Z","timestamp":1700009169101},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T00:00:00Z","timestamp":1218758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00108-008-2192-y","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T13:33:51Z","timestamp":1218634431000},"page":"1126-1136","source":"Crossref","is-referenced-by-count":3,"title":["Therapie der Osteoporose nach der \u201eEuropean Guidance 2008\u201c"],"prefix":"10.1007","volume":"49","author":[{"given":"R.","family":"Bartl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,15]]},"reference":[{"key":"2192_CR1","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00108-002-0758-7","volume":"43","author":"Bartl","year":"2002","unstructured":"Bartl R (2002) Osteoporose: Was ist gesichert in der Therapie? Internist 43: 1529\u20131543","journal-title":"Internist"},{"key":"2192_CR2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1055\/s-2007-979369","volume":"132","author":"Bartl","year":"2007","unstructured":"Bartl R (2007) Leitliniengerechtes Management der Osteoporose: Rationell \u2013 kostensparend \u2013 effektiv. Dtsch Med Wochenschr 132: 995\u2013999","journal-title":"Dtsch Med Wochenschr"},{"key":"2192_CR3","doi-asserted-by":"crossref","unstructured":"Bartl R (2008) Osteoporose \u2013 Pr\u00e4vention, Diagnostik, Therapie, 3. Aufl. Thieme, Stuttgart","DOI":"10.1055\/b-0034-8124"},{"key":"2192_CR4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00113-003-0642-5","volume":"106","author":"Bartl","year":"2003","unstructured":"Bartl R, Bartl C, Mutschler W (2003) Diagnostik und Therapie der Osteoporose: Strategie f\u00fcr eine effiziente Pr\u00e4vention von Folgefrakturen. Unfallchirurg 106: 526\u2013541","journal-title":"Unfallchirurg"},{"key":"2192_CR5","doi-asserted-by":"crossref","unstructured":"Bartl R, Frisch B, Tresckow E von, Bartl C (2007) Bisphosphonates in medical practice. Springer, Berlin Heidelberg New York","DOI":"10.1007\/978-3-540-69870-8"},{"key":"2192_CR6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00129-007-2050-3","volume":"40","author":"Bartl","year":"2007","unstructured":"Bartl R, Thaler C (2007) Leitliniengerechte Diagnostik und Therapie der postmenopausalen Osteoporose \u2013 eine neue Verantwortung f\u00fcr den Gyn\u00e4kologen. Gynakologe 40: 913\u2013923","journal-title":"Gynakologe"},{"key":"2192_CR7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809\u20131822","journal-title":"N Engl J Med"},{"key":"2192_CR8","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al.; FLEX Research Group(2006) Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927\u20132936","journal-title":"JAMA"},{"key":"2192_CR9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon D et al. (2007) Incidence and economic burden of osteoporostic-related fractures in the United States. 2005\u20132025. J Bone Miner Res 22: 465\u2013475","journal-title":"J Bone Miner Res"},{"key":"2192_CR10","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00198-006-0166-2","volume":"17","author":"Carr","year":"2006","unstructured":"Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17: 1638\u20131644","journal-title":"Osteoporos Int"},{"key":"2192_CR11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570\u2013578","journal-title":"Endocr Rev"},{"key":"2192_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"Cummings","year":"2006","unstructured":"Cummings SR, Karpf DB, Harris F et al. (2006) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281\u2013289","journal-title":"Am J Med"},{"key":"2192_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-004-1813-0","volume":"16","author":"Delmas","year":"2005","unstructured":"Delmas P, Rizzoli R, Cooper C (2005) Treatment of patients with postmenopausal osteoporosis is worthwile. The position of the International Osteoporosis Foundation. Osteoporos Int 16: 1\u20135","journal-title":"Osteoporos Int"},{"key":"2192_CR14","first-page":"B2199","volume":"39","author":"H\u00e4ussler","year":"2006","unstructured":"H\u00e4ussler B, Gothe H, Mangiapane S et al. (2006) Versorgung von Osteoporose-Patienten in Deutschland. Ergebnisse der BoneEVA-Studie. Dtsch Arztebl 39: B2199\u2013B2205","journal-title":"Dtsch Arztebl"},{"key":"2192_CR15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17: 1726\u20131733","journal-title":"Osteoporos Int"},{"key":"2192_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s001980200068","volume":"13","author":"Johnell","year":"2002","unstructured":"Johnell O, Oden A, De Laet C et al. (2002) Biochemical markers and the assessment of fracture probability. Osteoporos Int 13: 523\u2013526","journal-title":"Osteoporos Int"},{"key":"2192_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"Kanis","year":"2008","unstructured":"Kanis J, Burlet N, Cooper C et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal osteoporosis. Osteoporos Int 19: 399\u2013428","journal-title":"Osteoporos Int"},{"key":"2192_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","volume":"42","author":"Kanis","year":"2008","unstructured":"Kanis JA, Adams J, Borgstr\u00f6m F et al. (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42: 4\u201315","journal-title":"Bone"},{"key":"2192_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00198-004-1623-4","volume":"16","author":"Kanis","year":"2005","unstructured":"Kanis J, Johnell O, Oden A et al. (2005) Intervention threshholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16: 6\u201314","journal-title":"Osteoporos Int"},{"key":"2192_CR20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O et al. (2003) The components of excess mortality after hip fracture. Bone 32: 468\u2013473","journal-title":"Bone"},{"key":"2192_CR21","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al. the HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799\u20131809","journal-title":"N Engl J Med"},{"key":"2192_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","volume":"19","author":"Pazianas","year":"2008","unstructured":"Pazianas M, Blumentals W, Miller P (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19: 773\u2013778","journal-title":"Osteoporos Int"},{"key":"2192_CR23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V et al. (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19: 811\u2013818","journal-title":"Osteoporos Int"},{"key":"2192_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/17460816.1.1.37","volume":"1","author":"Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V (2006) Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol 1: 37\u201340","journal-title":"Future Rheumatol"},{"key":"2192_CR25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"Russell","year":"2008","unstructured":"Russell R, Watts N, Ebentino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733\u2013759","journal-title":"Osteoporos Int"},{"key":"2192_CR26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"Siris","year":"2004","unstructured":"Siris E, Chen Y, Abbott T et al. (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164: 1108\u20131112","journal-title":"Arch Intern Med"},{"key":"2192_CR27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00198-007-0511-0","volume":"19","author":"Zethraeus","year":"2008","unstructured":"Zethraeus N, Str\u00f6m O, Borgstr\u00f6m F et al. (2008) The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int 19: 819\u2013827","journal-title":"Osteoporos Int"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2192-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2192-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:10Z","timestamp":1558584730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2192-y"}},"subtitle":["Frakturorientiert \u2013 rationell \u2013 kosteneffektiv"],"short-title":[],"issued":{"date-parts":[[2008,8,15]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2192-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,15]]}}}